On August 13, PEGBIO CO-B rose 8.82% in regular trading, reaching HK$6.725, with turnover of approximately HK$90.85 million. The rally was driven by continued commercialization momentum of the company's core product Paidakang (visepegenatide injection).

On the news front, Paidakang has recently been prescribed at multiple medical institutions and online channels across China, triggering the second milestone royalty payment of approximately HK$49 million from Shanghai Tenry Pharmaceutical. Combined with the first payment of HK$61 million received in early June, the cumulative royalty payments triggered and received have reached approximately HK$110 million. Paidakang is a proprietary long-acting GLP-1 receptor agonist approved for the treatment of type 2 diabetes in adults.

The commercialization progress follows a series of catalysts including a strategic partnership signed in July with Tenry Pharmaceutical and Alibaba Health to accelerate market penetration through both offline hospital networks and digital patient access channels, as well as the product passing the preliminary review for national medical insurance catalog adjustment as an exclusive product.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)